New hypoglycemic effects of indorenate mediated by the 5-HT1a and 5-HT2a receptors: In vivo and in silico studies

The treatment of metabolic syndrome (MS), characterized by type 2 diabetes (T2D), obesity, dyslipidemias, and cardiovascular problems, requires an integral treatment. In addition to its central activity, serotonin also has peripheral effects, implying regulation of blood glucose and insulin levels. Indorenate is a serotonin analog with antihypertensive properties and possible activity on the metabolism of carbohydrates. However, its effect on glucose levels has not been explored, which is relevant in searching for the indorenate's potential as an alternative to the treatment of MS. This investigation aimed to study the effects of indorenate on glycemia through in vivo and in silico assays. In normal rats, indorenate was co-administered with two serotonergic antagonists: pelanserin (5-HT2a antagonist) and WAY-100635 (5-HT1a antagonist). Indorenate caused a hypoglycemic effect in normal rats. Pelanserin and WAY-100635 inhibited this effect. In diabetic rats, indorenate increased insulin l..., , # New hypoglycemic effects of indorenate mediated by the 5-HT1a and 5-HT2a receptors: In vivo and in silico studies

Dataset DOI: [10.5061/dryad.2jm63xt36](https://doi.org/10.5061/dryad.2jm63xt36)

## Description of the data and file structure

These data were used to perform the statistical analysis: Figure 2A (OGTT in normal male Wistar rats) 2-way ANOVA analysis of repeated measures complemented with Sidak test, for figure 2B (AUC of Figure 2A) data for a one-way ANOVA analysis posthoc Tukey-Kramer test, Figure 3A (Insulin secretion with glucose in normal Wistar rats) data 2-way ANOVA analysis of repeated measures complemented with Sidak test, 3B (Insulin secretion without glucose in normal Wistar rats) data 2-way ANOVA analysis of repeated measures complemented with Sidak test, Figure 3C (AUC insulin secretion with or without glucose in normal Wistar male rats) one-way ANOVA analysis posthoc Tukey-Kramer test, Figure 4 (Capilar glucose by the euglycemic clamp in an OGTT  in normal ..., , ,